All news

CG Oncology leads five biotech readouts, Aclaris trial fails

Alpha Vantage · kalkine.ca · · AI-summarised by FinFlash

CG Oncology (NASDAQ:CGON) posted the strongest of five biotech clinical readouts, with its Phase 3 bladder cancer trial showing a 68% lower risk of recurrence and driving a significant stock gain. Aclaris Therapeutics (NASDAQ:ACRS) fell after its Phase 2 eczema trial missed its primary endpoint, while Lexeo, Helus Pharma and Alpha Tau delivered mixed results.

Read original source

ACRS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.